Are you suffering or have you suffered from heavy periods caused by fibroids? Make a Difference in Women’s Healthcare. Participate in this survey for improving options for treating uterine fibroids.

If you are a woman between the ages of 21 and 50 who has had a hysterectomy, you can contribute to our research by answering a series of online questions that cover a variety of topics including demographic information, your hysterectomy procedure, and your sexuality. The study will take approximately 45 minutes to complete.

If you decide to continue, you will be presented with a study information sheet that will provide you with a more detailed explanation of the study as well as a consent form.

Thank you for your time and interest.

Loss of Desire/Libido Study - Post-menopause (Natural menopause or loss of ovaries)

You knew a lot would change when you went through menopause – whether it happened naturally or through surgery. But one thing you weren’t completely prepared for may have been finding yourself less interested in sex. You may have had a healthy sex life but now perhaps it seems no matter what you do, you can’t get in the mood. And these kind of problems aren’t limited to the bedroom, because your lack of sex drive places additional stress on other aspects of your life, such as your relationship with your significant other.

What you may not realize is your decrease in sexual desire is a common medical condition that affects many women just like you. After you go through menopause or have your ovaries removed, your body usually decreases its production of testosterone – a hormone that affects many things, including your sex drive. Though usually thought of as a male hormone, testosterone plays a role in many functions in women, including sex drive. Low testosterone may contribute to the symptoms of Hypoactive Sexual Desire Disorder (HSDD), which is the decrease or absence of desire for sex that causes personal distress and, possibly, relationship problems.

A medical research study is being conducted for women who have gone through menopause or had their ovaries removed and are experiencing a decrease in sexual desire. The study will include 3,500 patients nationwide.

The primary purpose of this study is to determine the safety and effectiveness of LibiGel®, an investigational medication for Hypoactive Sexual Desire Disorder (HSDD). If you are interested, you will be evaluated to further determine your eligibility. If you qualify, you will receive investigational medication, study-related medical exams and lab tests at no charge. You may also receive financial compensation for time and travel.

If you are interested in seeing if you may qualify for the study, call 1-877-BLOOM-81. You will learn more about the study and ask you a few questions to see if you are eligible. If you know of anyone else who might be interested in the study, please feel free to forward this email as you like.
We are looking forward to hearing from you about this study to help find a future treatment for women with low sexual desire.

Thank you

Visit WWW.BloomStudy.com or Call 1-877-BLOOM-81.

West Coast Clinical Trials

You may receive:
- Up to $2000 for time and travel
- Study-related examination at no cost
- Comfortable accommodations

Qualifications:
- Female
- 45 – 85 years old
- Generally healthy

Participation in a research study may contribute to medication development for the next generation.

Contact us NOW

West Coast Clinical Trials
1-877-777-9228
ptinfo@wcctrials.com
5630 Cerritos Ave., Cypress, CA 90630

February 22, 2006

Hystersister website users who have recently had a hysterectomy and have had their ovaries removed(within 1 month post-op) are invited to participate in a survey study by University of Iowa researchers. This web-based survey inquires about the experiences you've had following your hysterectomy. The survey may take 20-30 minutes to complete. You will also be invited to complete a follow-up web-based survey in 12 weeks. The Hystersisters website has generously agreed to award each woman who participates a Hystersisters gift badge for the time and effort to complete the initial survey. In addition, women who complete both the initial survey and the follow-up survey will receive a certificate of participation and will be entered into a raffle for a chance to receive $50.00.

July 1, 2005

If you have already had first line treatment for ovarian cancer, and your cancer has returned, you may be eligible to participate in a clinical research study investigating the safety and effectiveness of an investigational drug, in combination with standard chemotherapy. [Click Here]

Please consider volunteering. Ovarian Cancer is diagnosed in more than 25,000 women in the United States and 2,500 women in Canada each year. Your involvement in clinical research may help other women with ovarian cancer, as well as women yet to be diagnosed.

May 11, 2005

Hystersister website users who have recently had a hysterectomy (within 1 month post-op) are invited to participate in a survey study by University of Iowa researchers. This web-based survey inquires about the experiences you've had following your hysterectomy. The survey may take 20-30 minutes to complete. You will also be invited to complete a follow-up web-based survey in 12 weeks. The Hystersisters website has generously agreed to award each woman who participates a Hystersisters gift badge for the time and effort to complete the initial survey. In addition, women who complete both the initial survey and the follow-up survey will receive a certificate of participation and will be entered into a raffle for a chance to receive $50.00.

[Survey Closed. Thank you for your participation]

January 20, 2005

This is a Phase III clinical trial (research study) of OvaRex® MAb (oregovomab) for women who have been diagnosed with Stage III/Stage IV ovarian cancer. OvaRex is a monoclonal antibody that targets CA125, a marker found in the blood associated with ovarian cancer. OvaRex is designed to help each patient’s immune system recognize ovarian cancer cells and fight their disease.

In this study, OvaRex is being used at a time shortly after successful front line therapy when there is no standard treatment. This period of time is called “watchful waiting”, and currently there are no approved products to treat ovarian cancer at this stage.

Click Here for More Info

December, 2004


Doctoral candidate is looking for any woman who has had a Hysterectomy under one year, or over more than a year ago for a Dissertation Study on Hysterectomy Outcomes.

Age is open, but all eligible participants must be involved in an intimate partner relationship and be willing to answer three Survey instruments about their sexual functioning, physical and emotional health, and partner relationship.

[Survey Closed. Thank you for your participation!]

November, 2004 - Ongoing


New clinical studies are being conducted throughout the U.S. to evaluate the safety and efficacy of Alista™, a topically applied product for the treatment of women with female sexual arousal disorder (FSAD) as a result of undergoing a hysterectomy. As there are no medications currently approved by the FDA for the treatment of diminished sexual arousal, these clinical studies are an important step in the development of new therapeutic options to provide women with useful treatments for decreased sexual arousal.

Click for more information